Background Adults with congenital heart disease (ACHD) and atrial arrhythmias (AA) face
an increased risk of thromboembolic events. Limited data exist on the use of non-vitamin K …

Introduction The risk for stroke in adults with congenital heart disease (ACHD) is increased,
especially in the setting of commonly ensuing atrial arrhythmias (AA), namely atrial …

In this issue of the Journal of the American College of Cardiology, the work described by
Payne et al 1 from around the world provides very important data on the use of apixaban for …

Background Children with heart disease frequently require anticoagulation for
thromboprophylaxis. Current standard of care (SOC), vitamin K antagonists or low-molecular …

Background Direct oral anticoagulants use in pediatric cardiology is poorly defined.
Objective We present the largest experience of apixaban use in children with heart disease …

Background Apixaban is a non–vitamin K oral anticoagulant approved for prevention of
stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). Current …

Background Current guidelines consider vitamin K antagonists (VKA) the oral anticoagulant
agents of choice in adults with atrial arrhythmias (AA) and moderate or complex forms of …

Background—Apixaban is approved for the prevention of stroke and systemic embolism in
patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke …

Introduction Patients with atrial fibrillation (AF) should be prescribed standard-dose (5mg
twice daily) apixaban for stroke prevention unless they meet 2 or more criteria: age≥ 80 …

Aims It is uncertain whether the benefit from apixaban varies by type and duration of atrial
fibrillation (AF). Methods and results A total of 18 201 patients with AF [2786 (15.3%) with …